Generic Version of Hepatitis C Treatment can Improve Life Expectancy
A new study reports that generic varieties of drug antivirals for treatment of Hepatitis C infections are cost-effective and can improve life expectancy with less complications.
Study was carried out by researcher Dr Rakesh Aggarwal from the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. Results of the study show that the generic versions of drugs such as Sofosbuvir, Ledipasvir, and Daclatasvir are cost-effective for Indian patients. Lifetime healthcare costs was observed to be reduced by around Rs 84, 000 per person while the life expectancy increased by eight years as compared to those who did not receiving any treatment. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe
The treatment with generic drugs became cost-effective within two years and cost-saving within 10 years of starting treatment. Cost saving was sooner for patients with the advanced disease across all age groups irrespective of the gender. The findings of the study encourage people suffering from Hepatitis C to opt for generic medicines to prevent complications and motivate doctors and policy makers to focus on the treatment of patients with advanced disease.
A total of 11 million people in India are suffering from chronic Hepatitis C infection, which is a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and other liver-related disorders. Hepatitis C infection have major economic implications due to expenditure on testing, treatment, and number of working hours.
According to Generic Drugs Market report Published by Coherent Market Insights, generic drugs yield the same therapeutic effect and are prescribed in the same dosing, with the same quality, and same the way of consumption and usage. Major advantage of generic drug is that they are cost-effective and affordable. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe
You may be interested
Smart Nanotechnology Enlivens Wooden Ships and ArtifactsMohit Joshi - January 28, 2019
Scientists developed an innovative approach using ‘smart’ nanocomposites to conserve 16th-century British warship, the Mary Rose, and its artifacts. Shipwrecks are preserved in sediments under cold water,…
Researchers Discovered New Properties of Ferroelectric CrystalMohit Joshi - January 25, 2019
Researchers discovered new properties of ferroelectric crystal, according to a study published on July 10, 2018. This study was conducted by a team of researchers from China.…
Researchers Develop Novel Antibody to Knockdown of Protein in VertebratesMohit Joshi - January 24, 2019
Researchers from Technische Universität Dresden developed a synthetic antibody that improves functional analysis of proteins. A research led by Dr. Jörg Mansfeld of the Biotechnology Center of…